|The new law of January 2015 has altered the regulatory framework of the Brazilian healthcare industry, allowing the entry of foreign investment. This brings Brazil into the context of international investments, not only of funds but also of major groups in the industry.
These developments show that the healthcare sector in Brazil has undergone major changes that are creating significant opportunities for new investments in a sector with high growth potential. The entry of foreign capital and the recent mergers and acquisitions within the industry are a clear sign of the opportunities that exist. Some examples are the cases of Amil and UnitedHealth, Rede D’Or and Carlyle, DASA, and Patria, among others.
The event will provide a global perspective on the recent developments in Brazil, explain the new legislation and its implications, and discuss investment and business opportunities in various sectors of the industry.
Luis Russo, MD, Founder and Director, CCBR/Bioclinica BrazilCharles Schmidt, MD, Medical Manager, Central Institute of Clinical Research, Hospital de Clínicas, and Attending Physician in Coordinating the Post-Graduate Program in Clinical Research, Santa Casa Medical SchoolOpening
Andrew L. Bab, Partner, Debevoise & Plimpton LLPFrancisco Balestrin, President, ANAHP – National Association of Private Hospitals and VP, Rede Vita
How the New Law will Change the Brazilian Healthcare Sector
Doing Business in the Healthcare Sector in Brazil
Elysangela Rabelo, Partner, TozziniFreire Advogados
Clinical Research Centers
Diagnostics Labs and Specialty Clinics
8:00 a.m. to 8:30 a.m. – Registration, Breakfast and Networking Session
8:30 a.m. to 10:30 a.m. – Presentation, Panel Discussion and Q&A
Member Price: $35
Non-Member Price: $70
Click here to register online.
Click here to download the registration form.